The Universities of Edinburgh and Glasgow are leading the Scottish Genomes Partnership (SGP) in collaboration with the NHS in both Scotland and England, and Genomics England.
The SGP was founded by the Universities of Edinburgh and Glasgow following a £15m investment in January 2015, which has led to installation of 10 state-of-the-art HiSeq X genome sequencing instruments divided between the sequencing hubs within the two Universities. A further £6m investment jointly awarded by Scotland’s Chief Scientist Office (£4m) and the UK’s Medical Research Council (£2m) in February 2016 has boosted the project enabling sequencing of the genomes of over 3,000 people in Scotland. This will offer significant new opportunities for diagnosis and management of diseases for patients in the Scottish NHS.
Linking genetic data from sequenced genomes with clinical information will enable precise, molecular diagnoses for patients, leading to personalised treatment and safer selection of drug therapies. It will also bring new understanding of the causes of both rare and common diseases, opening the door to the development of new treatments.
The Partnership will initially focus on rapid screening of cancer patients, diagnosing childhood illnesses, rare genetic diseases, disorders of the central nervous system and population studies.
The co-Directors are Prof Tim Aitman (University of Edinburgh) and Prof Andrew Biankin (University of Glasgow).
Prof. Tim Aitman
Prof. Andrew Biankin